Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Osteoporosis 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Lymphoma 1Leukemia 1Kidney Neoplasms 1Giant Cell Tumor of Bone 1Depression 1Colonic Polyps 1Carcinoma, Transitional Cell 1Body Weight Changes 1Arthralgia 1Adenomatous Polyps 1

Interventions

Gemcitabine 6Specimen Handling 4Cisplatin 4pembrolizumab 3enfortumab vedotin 3atezolizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3vinflunine 2eribulin 2avelumab 2Standard of Care 2Biopsy 2vandetanib 1tocilizumab 1tamibarotene 1rucaparib 1relatlimab 1pegfilgrastim 1merphos 1guadecitabine 1genexol-PM 1dehydroftorafur 1carotuximab 1Vitamin D 1Vinblastine 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ureteral Neoplasms × Calcium × Clear all
NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

University Health Network, Toronto

Phase 2 Completed
6 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡